Cargando…
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
We have recently described Pz-1, a benzimidazole-based type-2 RET and VEGFR2 inhibitor. Based on a kinome scan, here we show that Pz-1 is also a potent (IC(50) < 1 nM) TRKA/B/C inhibitor. Pz-1 potently inhibited proliferation of human cancer cells carrying either RET- or TRKA oncoproteins (IC(50)...
Autores principales: | Moccia, Marialuisa, Yang, Donglin, Lakkaniga, Naga Rajiv, Frett, Brendan, McConnell, Nicholas, Zhang, Lingtian, Brescia, Annalisa, Federico, Giorgia, Zhang, Lingzhi, Salerno, Paolo, Santoro, Massimo, Li, Hong-yu, Carlomagno, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352932/ https://www.ncbi.nlm.nih.gov/pubmed/34373541 http://dx.doi.org/10.1038/s41598-021-95612-4 |
Ejemplares similares
-
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor
Optimized for Single-Agent Polypharmacology
por: Moccia, Marialuisa, et al.
Publicado: (2020) -
Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015) -
RET Gene Fusions in Malignancies of the Thyroid and Other Tissues
por: Santoro, Massimo, et al.
Publicado: (2020) -
Rational Design, Synthesis and Biological Evaluation of Pyrimidine-4,6-diamine derivatives as Type-II inhibitors of FLT3 Selective Against c-KIT
por: Bharate, Jaideep B., et al.
Publicado: (2018) -
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)